Prophylactic Reinforcement of Ventral Abdominal Incisions Trial

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
C. R. Bard
Study ID
NCT03911700
Status
Recruiting

Conditions

  • Open Midline Laparotomy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Phasix™ Mesh — DEVICE
    Phasix™ Mesh is a resorbable mesh prepared from Poly-4-hydroxybutyrate (P4HB).

Study Details

This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.

Key Dates

Start date
Dec 12, 2019
Status verified
Feb 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2031

Study Design

Enrollment
477 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Phasix™ Mesh
    Prophylactic onlay placement of mesh.
  • No Intervention: Primary Suture Closure
    Standard Fascial closure.

Primary Outcome Measure

Rate of Incisional Hernia [ Time Frame: 24-Months ]

Central Contacts

Locations (30)

FacilityCityStateZIPSite coordinators
Dignity HealthPhoenixArizona85013
Mitzy Vazquezgamez
602-406-5260
Hahn Soe-Lin, MD (PRINCIPAL_INVESTIGATOR)
Keck Medical Center of USCLos AngelesCalifornia90033-
University of California San FranciscoSan FranciscoCalifornia94143
Angelina Phan
415-353-3463
Hobart Harris, MD (PRINCIPAL_INVESTIGATOR)
Hartford HospitalHartfordConnecticut06102-
St. Francis Hospital and Medical CenterHartfordConnecticut06105-
Emory UniversityAtlantaGeorgia30322-
OSF Saint Francis Medical CenterPeoriaIllinois61637-
Indiana UniversityIndianapolisIndiana46202-
University of Kentucky Research FoundationLexingtonKentucky40508
Sydney Cloyd
859-218-5151
Scott J Roth, MD (PRINCIPAL_INVESTIGATOR)
Tulane University School of MedicineNew OrleansLouisiana70112
Delainna Bartholomew
504-988-6902
Jennifer Silinsky, MD (PRINCIPAL_INVESTIGATOR)
University of MichiganAnn ArborMichigan48109-
Minneapolis VA Health Care SystemMinneapolisMinnesota55417-
University of MinnesotaMinneapolisMinnesota55455
Kathryn Vera
612-625-5018
Wolfgang Gaertner, MD (PRINCIPAL_INVESTIGATOR)
St. Luke's HospitalKansas CityMissouri64111-
Cox HealthSpringfieldMissouri65807-
Washington UniversitySt LouisMissouri63110
Anna Rois
314-362-5705
William Chapman, MD (PRINCIPAL_INVESTIGATOR)
Nebraska Medical CenterOmahaNebraska68106-
Nebraska Methodist HospitalOmahaNebraska68114-
Rutgers Cancer Institute of New JerseyNew BrunswickNew Jersey08901
Christian Misdary
732-235-8591
Henry Alexander, MD (PRINCIPAL_INVESTIGATOR)
New York Presbyterian Hospital-Columbia University Medical CenterNew YorkNew York10032-
Montefiore Medical CenterThe BronxNew York10467-
Atrium HealthCharlotteNorth Carolina28203-
Duke UniversityDurhamNorth Carolina27708-
New Hanover Regional Medical CenterWilmingtonNorth Carolina28401
Samanthan Straka
910-667-9424
William Hope, MD (PRINCIPAL_INVESTIGATOR)
The Ohio State UniversityColumbusOhio43210
Kayla Diaz
614-293-8549
Benjamin Poulose, MD (PRINCIPAL_INVESTIGATOR)
Oregon Health & Science UniversityPortlandOregon97239-
University of PennsylvaniaPhiladelphiaPennsylvania19104
Carolina Reyes
215-615-8036
Robert Roses, MD (PRINCIPAL_INVESTIGATOR)
Baptist Clinical Research InstituteMemphisTennessee38163-
Vanderbilt UniversityNashvilleTennessee37232
Kimberly Fields
615-875-4658
Richard Pierce, MD (PRINCIPAL_INVESTIGATOR)
CAMC Health Education and Research Institute, Inc.CharlestonWest Virginia25304-

Find similar trials in Phoenix, AZ